Annovis Bio Statistics
Total Valuation
Annovis Bio has a market cap or net worth of $51.55 million. The enterprise value is $32.82 million.
| Market Cap | 51.55M |
| Enterprise Value | 32.82M |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, before market open.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Annovis Bio has 42.61 million shares outstanding. The number of shares has increased by 73.71% in one year.
| Current Share Class | 42.61M |
| Shares Outstanding | 42.61M |
| Shares Change (YoY) | +73.71% |
| Shares Change (QoQ) | +34.73% |
| Owned by Insiders (%) | 11.11% |
| Owned by Institutions (%) | 22.25% |
| Float | 35.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.47
| Current Ratio | 3.47 |
| Quick Ratio | 2.95 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -703.68% and return on invested capital (ROIC) is -439.86%.
| Return on Equity (ROE) | -703.68% |
| Return on Assets (ROA) | -142.36% |
| Return on Invested Capital (ROIC) | -439.86% |
| Return on Capital Employed (ROCE) | -315.92% |
| Weighted Average Cost of Capital (WACC) | 11.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$7.07M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.70% in the last 52 weeks. The beta is 1.23, so Annovis Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | -46.70% |
| 50-Day Moving Average | 1.50 |
| 200-Day Moving Average | 2.11 |
| Relative Strength Index (RSI) | 42.50 |
| Average Volume (20 Days) | 883,120 |
Short Selling Information
The latest short interest is 6.02 million, so 14.13% of the outstanding shares have been sold short.
| Short Interest | 6.02M |
| Short Previous Month | 4.96M |
| Short % of Shares Out | 14.13% |
| Short % of Float | 16.98% |
| Short Ratio (days to cover) | 5.14 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -49.53M |
| Pretax Income | -49.52M |
| Net Income | -49.52M |
| EBITDA | n/a |
| EBIT | -49.53M |
| Earnings Per Share (EPS) | -$1.79 |
Balance Sheet
The company has $18.73 million in cash and no debt, with a net cash position of $18.73 million or $0.44 per share.
| Cash & Cash Equivalents | 18.73M |
| Total Debt | n/a |
| Net Cash | 18.73M |
| Net Cash Per Share | $0.44 |
| Equity (Book Value) | -4.25M |
| Book Value Per Share | -0.10 |
| Working Capital | 15.68M |
Cash Flow
| Operating Cash Flow | -43.34M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -43.34M |
| FCF Per Share | -$1.02 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Annovis Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -73.71% |
| Shareholder Yield | -73.71% |
| Earnings Yield | -96.06% |
| FCF Yield | -84.07% |
Analyst Forecast
The average price target for Annovis Bio is $10.50, which is 767.77% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.50 |
| Price Target Difference | 767.77% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |